#India #Intas Pharmaceuticals #Ahmedabad #Accord Healthcare #Prothya Biosolutions

Accord Completes Acquisition of Prothya Biosolutions

Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has recently made headlines by announcing its acquisition of Prothya Biosolutions Belgium BV. This strategic move aims to enhance Accord's global footprint in the plasma-derived medicines market.

The acquisition encompasses Prothya Biosolutions and all its subsidiaries, a major player in the collection and production of plasma-derived therapies primarily based in the Netherlands and Belgium. While the deal hinges on customary closing conditions, including regulatory approvals, it is projected to finalize soon.

An Ambitious Leap Towards Global Expansion

This acquisition marks a significant step for Intas Pharmaceuticals and Accord towards their long-standing ambition of establishing a robust international presence in the plasma-derived therapeutics sector. With Prothya’s established influence extending to Amsterdam and Brussels, alongside plasma collection facilities in Hungary, the acquisition is set to bolster Accord’s leadership in the field.

Intas currently operates a plasma division in India, where it has supplied plasma-derived medicines to hospitals since 2015, operating on an impressive annual plasmapheresis capacity exceeding one million liters. This synergistic acquisition will allow for further advancements and enhancements in plasma processing capabilities in conjunction with Accord’s existing operations, particularly with the expansion of Intas' facilities in Gujarat.

The Voice of Leadership

Commenting on the acquisition, Binish Chudgar, President of Intas and Accord, expressed enthusiasm about the merger. He emphasized the strategic importance of this acquisition, highlighting that it creates an expansive platform for plasma sourcing that aims ultimately to serve patients globally with essential therapies that often face under-prescription.

Nir Epstein, the CEO of Prothya, pointed out the company’s remarkable growth over the past four years, including establishing a network for plasma collection in Hungary. He also acknowledged the dedicated Prothya team and expressed confidence that being part of Accord will propel the company into a new phase of growth.

Market Potential and Future Implications

According to market analyses, the global plasma-derived medicines market—particularly the intravenous immunoglobulin (IgIV) segment—is currently valued at around $30 billion, with projections to surge to $50 billion by 2035. This acquisition uniquely positions Intas to tap into significant plasma processing capacity and an expansive commercial presence across 85 countries.

BofA Securities acted as the exclusive financial advisor to Accord in this strategic transaction, while Evercore served as the exclusive financial advisor to Prothya. This partnership is expected not only to enhance the operational capabilities of both companies but also to fundamentally contribute to the broader accessibility of life-saving plasma-derived medications.

About Intas Pharmaceuticals

Established in Ahmedabad, India, Intas Pharmaceuticals is a vertically integrated pharmaceutical company, recognized for its comprehensive capabilities in drug formulation development and marketing. With a firm commitment to expanding healthcare access globally, Intas operates an extensive network under the Accord Healthcare banner, enhancing its reach across key markets worldwide. Over the years, Intas has adopted both organic growth strategies and acquisitions to broaden its product portfolio and operations significantly. Currently, it serves more than 85 countries and sustains robust marketing and distribution infrastructures spanning North America, Europe, Latin America, Asia-Pacific, the CIS, and MENA regions. The notable success of Intas in major pharmaceutical markets has helped solidify its reputation as a global brand.

In conclusion, the integration of Prothya Biosolutions into Accord's operations marks a significant milestone in the evolving landscape of the plasma-derived medicines industry, with substantial implications for patient care and global health.